Viking Therapeutics, Inc. (VKTX): Price and Financial Metrics


Viking Therapeutics, Inc. (VKTX)

Today's Latest Price: $6.02 USD

0.65 (-9.75%)

Updated Sep 23 4:00pm

Add VKTX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

VKTX Daily Price Range
VKTX 52-Week Price Range

VKTX Stock Price Chart Technical Analysis Charts


VKTX Price/Volume Stats

Current price $6.02 52-week high $8.87
Prev. close $6.67 52-week low $3.26
Day low $6.00 Volume 1,187,272
Day high $6.69 Avg. volume 1,436,549
50-day MA $6.99 Dividend yield N/A
200-day MA $6.69 Market Cap 438.00M

Viking Therapeutics, Inc. (VKTX) Company Bio


Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.


VKTX Latest News Stream


Event/Time News Detail
Loading, please wait...

VKTX Latest Social Stream


Loading social stream, please wait...

View Full VKTX Social Stream

Latest VKTX News From Around the Web

Below are the latest news stories about Viking Therapeutics Inc that investors may wish to consider to help them evaluate VKTX as an investment opportunity.

Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK0214

SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 1 single ascending dose…

PR Newswire | September 9, 2020

Viking Therapeutics to Participate in Upcoming Investor Conferences

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in four upcoming investor conferences.

Yahoo | September 2, 2020

2 Great Stocks Under $10

Bargain stocks don't come much cheaper than this.

Yahoo | September 2, 2020

Buy the Dip in Viking Therapeutics Stock, Says Analyst

Last week ended on a disappointing note for investors of NASH drug developer Viking Therapeutics (VKTX). Successive days in the red resulted in a cumulative share loss of 13%. The sell-off was instigated by two seemingly negative events.Firstly, Viking presented data from the Phase 2 study of VK2809

Yahoo Finance | September 1, 2020

VKTX: Continued Liver Fat Reductions Four Weeks Following Final Dose of VK2809 in Phase 2 Trial…

By David Bautz, PhD NASDAQ:VKTX READ THE FULL VKTX RESEARCH REPORT Business Update New Data Presented at EASL 2020 On August 28, 2020, Viking Therapeutics, Inc. (NASDAQ:VKTX) announced new data from the Phase 2 clinical trial of VK2809 in patients with non-alcoholic fatty liver disease (NAFLD) and elevated low density lipoprotein (LDL) cholesterol were presented at EASL 2020. The new results

Yahoo | August 31, 2020

Read More 'VKTX' Stories Here

VKTX Price Returns

1-mo -22.82%
3-mo -22.42%
6-mo 32.89%
1-year -8.51%
3-year 333.09%
5-year 2.21%
YTD -24.94%
2019 4.84%
2018 88.42%
2017 241.18%
2016 -65.10%
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6457 seconds.